Patent · US Active

Tissue factor-targeted antibody-drug conjugate

US12290505B2 · kind B2 · utility

0Cited by

7References

13Claims

0Family size

Assignees

FUDAN UNIVERSITY · CN
SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES · CN
SHANGHAI MIRACOGEN INC. · CN

Inventors

Ke Yu · Alpharetta, US
Jingkang Shen · Shanghai, CN
Tao Meng · North Plainfield, US
Lanping Ma · Shanghai, CN
Xuesai Zhang · Shanghai, CN
Qingrou Li · Shanghai, CN
Qing Lin · San Diego, US

Key dates

Filing date	Oct 27, 2022
Grant date	May 6, 2025
Priority date	—
Expiry date	Mar 3, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/90
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A tissue factor (TF)-targeted antibody-drug conjugate (ADC) and a method for preparing the ADC. The ADC is capable of binding to TF antigen with high specificity, and has high affinity, low immunogenicity, high cytotoxicity, and significant anti-tumor activity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.